{"id":"eprosartan","rwe":[{"pmid":"41378994","year":"2026","title":"Decoding the Neuroprotective Intervention of Angiotensin Receptor Blockers: A Multimodal Approach Using In Silico Network Pharmacology, Molecular Modeling, and In Vivo Validation of Key Markers.","finding":"","journal":"ACS chemical neuroscience","studyType":"Clinical Study"},{"pmid":"40886946","year":"2025","title":"Eprosartan alleviates the traumatic brain injury-induced multi-organ dysfunction syndrome in mice via AT(1)R/SNS/HMGB1 blockade and PDL-1 modulation.","finding":"","journal":"Molecular and cellular neurosciences","studyType":"Clinical Study"},{"pmid":"40440958","year":"2025","title":"Modulating the renin-angiotensin system by eprosartan or xanthenone drives microglial M2 polarization in a rat model of Parkinson's disease via regulating the interplay between MKP-1/ miR-155 /SOCS1 and PP2A signaling network.","finding":"","journal":"International immunopharmacology","studyType":"Clinical Study"},{"pmid":"40190631","year":"2025","title":"Unraveling PPARβ/δ nuclear receptor agonists via a drug-repurposing approach: HTVS-based ligand identification, molecular dynamics, pharmacokinetics, and in vitro anti-steatotic validation.","finding":"","journal":"RSC advances","studyType":"Clinical Study"},{"pmid":"39945248","year":"2025","title":"Eprosartan Reduces Inflammation and Oxidative Stress in Ethanol-induced Hepatotoxicity.","finding":"","journal":"Current pharmaceutical design","studyType":"Clinical Study"}],"tags":[{"label":"Angiotensin 2 Receptor Blocker","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Type-1 angiotensin II receptor","category":"target"},{"label":"AGTR1","category":"gene"},{"label":"C09CA02","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Abbvie","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Angiotensin II Type 2 Receptor Blockers","category":"pharmacology"},{"label":"Angiotensin Receptor Antagonists","category":"pharmacology"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":36.82,"date":"","count":7,"signal":"Splenic rupture","source":"DrugCentral FAERS","actionTaken":"Reported 7 times (LLR=37)"}],"drugInteractions":[{"url":"/drug/indomethacin","drug":"indomethacin","action":"Monitor closely","effect":"May interact with Indomethacin","source":"DrugCentral","drugSlug":"indomethacin"},{"url":"/drug/lithium","drug":"lithium","action":"Monitor closely","effect":"May interact with Lithium","source":"DrugCentral","drugSlug":"lithium"},{"url":"/drug/spironolactone","drug":"spironolactone","action":"Monitor closely","effect":"May interact with Spironolactone","source":"DrugCentral","drugSlug":"spironolactone"},{"url":"/drug/triamterene","drug":"triamterene","action":"Monitor closely","effect":"May interact with Triamterene","source":"DrugCentral","drugSlug":"triamterene"}],"commonSideEffects":[{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"","severity":"common","organSystem":""},{"effect":"Upper respiratory tract infection","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"","severity":"common","organSystem":""},{"effect":"Coughing","drugRate":"","severity":"common","organSystem":""},{"effect":"Pharyngitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Rhinitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Bronchitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Asthenia","drugRate":"","severity":"common","organSystem":""},{"effect":"Peripheral edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Insomnia","drugRate":"","severity":"common","organSystem":""},{"effect":"Anxiety","drugRate":"","severity":"common","organSystem":""},{"effect":"Depression","drugRate":"","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"","severity":"common","organSystem":""},{"effect":"Hyperkalemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypotension","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Acute pancreatitis","Anuria","Azotemia","Dehydration","Diabetes mellitus","Gout","Hepatic coma","Hypercalcemia","Hypercholesterolemia","Hyperkalemia","Hyperparathyroidism","Hyperuricemia","Hypochloremic alkalosis","Hypokalemia","Hypomagnesemia","Hyponatremia","Hypovolemia","Low blood pressure","Neonatal hyperbilirubinemia","Pregnancy, function","Renal artery stenosis","Secondary angle-closure glaucoma","Sympathectomy","Systemic lupus erythematosus"],"specialPopulations":{"Pregnancy":"Pregnancy Category (first trimester) and (second and third trimesters): See WARNINGS: Fetal/Neonatal Morbidity and Mortality.","Geriatric use":"In the controlled clinical trials where patients received eprosartan/hydrochlorothiazide combination therapy, 15% to 33% of the patients were 65 years of age or greater. There was no difference in the effect of TEVETEN(R) HCT 600/12.5 mg treatment according to age. However, following single oral dose administration of eprosartan to healthy elderly men, (aged 68 to 78 years), AUC, Cmax, and Tmax eprosartan values increased, on average, by approximately twofold, compared to healthy young men.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established."},"seriousAdverseEvents":[{"effect":"Atrial fibrillation","drugRate":"","severity":"serious"},{"effect":"Angina pectoris","drugRate":"","severity":"serious"},{"effect":"Myocardial infarction","drugRate":"","severity":"serious"},{"effect":"Stroke","drugRate":"","severity":"serious"},{"effect":"Syncope","drugRate":"","severity":"serious"},{"effect":"Anaphylaxis","drugRate":"","severity":"serious"},{"effect":"Hepatic dysfunction","drugRate":"","severity":"serious"},{"effect":"Renal failure","drugRate":"","severity":"serious"},{"effect":"Hyperkalemia","drugRate":"","severity":"serious"},{"effect":"Angioedema","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"company":"AbbVie","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=EPROSARTAN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:39:16.938244+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Eprosartan","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:39:24.123784+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:39:22.166737+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPROSARTAN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:39:23.086041+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Type-1 angiotensin II receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:39:24.123715+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200987/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:39:23.792591+00:00"}},"allNames":"teveten","offLabel":[],"synonyms":["SKF-108566","eprosartan","eprosartan mesylate","eprosartan mesilate"],"timeline":[{"date":"1997-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from ABBVIE to Abbvie"},{"date":"1997-12-22","type":"positive","source":"DrugCentral","milestone":"FDA approval (Abbvie)"},{"date":"2011-11-16","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"}],"aiSummary":"Teveten (EPROSARTAN) is a small molecule Angiotensin 2 Receptor Blocker that targets the Type-1 angiotensin II receptor. Originally developed by Abbvie, it was FDA approved in 1997 for the treatment of hypertensive disorder. As an off-patent medication, it is available as a generic. Teveten has a relatively short half-life of 2.1 hours and low bioavailability of 13%. It is currently owned by Abbvie.","approvals":[{"date":"1997-12-22","orphan":false,"company":"ABBVIE","regulator":"FDA"}],"brandName":"Teveten","ecosystem":[{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null}],"mechanism":{"target":"Type-1 angiotensin II receptor","novelty":"Follow-on","targets":[{"gene":"AGTR1","source":"DrugCentral","target":"Type-1 angiotensin II receptor","protein":"Type-1 angiotensin II receptor"}],"moaClass":"Angiotensin 2 Receptor Antagonists","modality":"Small Molecule","drugClass":"Angiotensin 2 Receptor Blocker","explanation":"","oneSentence":"","technicalDetail":"Teveten selectively blocks the angiotensin II type 1 receptor (AT1R), preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II, thereby reducing blood pressure."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Eprosartan","title":"Eprosartan","extract":"Eprosartan, sold under the brand name Teveten among others, is an angiotensin II receptor antagonist used for the treatment of high blood pressure.","wiki_history":"== History ==\nThe compound came into the Abbott Laboratories cardiovascular pipeline with its acquisition of Kos Pharmaceuticals in 2006, which had licensed it, along with \"a range of hypertensive treatments\", from the Biovail Corporation."},"commercial":{"launchDate":"1997","_launchSource":"DrugCentral (FDA 1997-12-22, ABBVIE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1037","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=EPROSARTAN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPROSARTAN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Eprosartan","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:04:21.539614","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:39:38.848630+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"losartan","drugSlug":"losartan","fdaApproval":"1995-04-14","patentExpiry":"Oct 7, 2041","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"valsartan","drugSlug":"valsartan","fdaApproval":"1996-12-23","genericCount":22,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"irbesartan","drugSlug":"irbesartan","fdaApproval":"1997-09-30","genericCount":23,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"candesartan cilexetil","drugSlug":"candesartan-cilexetil","fdaApproval":"1998-06-04","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"telmisartan","drugSlug":"telmisartan","fdaApproval":"1998-11-10","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"olmesartan medoxomil","drugSlug":"olmesartan-medoxomil","fdaApproval":"2002-04-25","genericCount":25,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"azilsartan medoxomil","drugSlug":"azilsartan-medoxomil","fdaApproval":"2011-02-25","relationship":"same-class"}],"genericName":"eprosartan","indications":{"approved":[{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA","eligibility":"Adults, not indicated for initial therapy"}],"offLabel":[{"name":"Atrial fibrillation","source":"DrugCentral","drugName":"EPROSARTAN"},{"name":"Chronic heart failure","source":"DrugCentral","drugName":"EPROSARTAN","evidenceCount":14,"evidenceLevel":"moderate"},{"name":"Diabetic renal disease","source":"DrugCentral","drugName":"EPROSARTAN","evidenceCount":10,"evidenceLevel":"emerging"},{"name":"Diastolic heart failure","source":"DrugCentral","drugName":"EPROSARTAN","evidenceCount":6,"evidenceLevel":"emerging"},{"name":"Nondiabetic Proteinuric Nephropathy","source":"DrugCentral","drugName":"EPROSARTAN","evidenceCount":0,"evidenceLevel":"emerging"}],"pipeline":[]},"currentOwner":"Abbvie","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"losartan","brandName":"losartan","genericName":"losartan","approvalYear":"1995","relationship":"same-class"},{"drugId":"valsartan","brandName":"valsartan","genericName":"valsartan","approvalYear":"1996","relationship":"same-class"},{"drugId":"irbesartan","brandName":"irbesartan","genericName":"irbesartan","approvalYear":"1997","relationship":"same-class"},{"drugId":"candesartan-cilexetil","brandName":"candesartan cilexetil","genericName":"candesartan cilexetil","approvalYear":"1998","relationship":"same-class"},{"drugId":"telmisartan","brandName":"telmisartan","genericName":"telmisartan","approvalYear":"1998","relationship":"same-class"},{"drugId":"olmesartan-medoxomil","brandName":"olmesartan medoxomil","genericName":"olmesartan medoxomil","approvalYear":"2002","relationship":"same-class"},{"drugId":"azilsartan-medoxomil","brandName":"azilsartan medoxomil","genericName":"azilsartan medoxomil","approvalYear":"2011","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":["Post-stroke Pneumonia"],"enrollment":13656,"completionDate":"2026-08-19"},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":["Sacubitril/Valsartan","Hypertension","Obesity"],"enrollment":180,"completionDate":"2027-06-30"},{"nctId":"NCT02024100","phase":"","title":"Observational Study to Investigate the Effectiveness of Eprosartan on Pulse Pressure (Teveten_MS)","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2014-02-06","conditions":["Hypertension"],"enrollment":109,"completionDate":"2016-12-26"},{"nctId":"NCT02817360","phase":"PHASE4","title":"NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients","status":"RECRUITING","sponsor":"Martin Huelsmann","startDate":"2016-02","conditions":["Heart Diseases","Diabetes Mellitus, Type 2"],"enrollment":2400,"completionDate":"2026-12"},{"nctId":"NCT04606563","phase":"PHASE3","title":"Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?","status":"TERMINATED","sponsor":"University of British Columbia","startDate":"2020-10-09","conditions":["Covid19","SARS-CoV Infection"],"enrollment":341,"completionDate":"2022-04-22"},{"nctId":"NCT04394117","phase":"PHASE4","title":"Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease","status":"COMPLETED","sponsor":"The George Institute","startDate":"2020-06-19","conditions":["Coronavirus Disease 2019","COVID-19"],"enrollment":787,"completionDate":"2022-01-17"},{"nctId":"NCT04954560","phase":"NA","title":"Effect of Losartan or Eprosartan on Fructose Hyperuricemia","status":"COMPLETED","sponsor":"Medical University of Lodz","startDate":"2008-01-01","conditions":["Uric Acid Concentration, Serum, Quantitative Trait Locus 7"],"enrollment":16,"completionDate":"2010-01-01"},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":["Hypertension","COVID"],"enrollment":22213,"completionDate":"2020-12-31"},{"nctId":"NCT04743063","phase":"","title":"Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-01-14","conditions":["Heart Failure, Systolic","Frailty"],"enrollment":40000,"completionDate":"2022-12-31"},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":["Hypertension","COVID-19"],"enrollment":2414,"completionDate":"2021-12-01"},{"nctId":"NCT01715584","phase":"PHASE4","title":"Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2012-07","conditions":["Hypertension"],"enrollment":80,"completionDate":"2019-12-31"},{"nctId":"NCT01562613","phase":"","title":"A Blood Pressure Regulation and Stroke Risk Evaluation Study in Hypertensive Patients Treated With Eprosartan","status":"COMPLETED","sponsor":"Abbott","startDate":"2012-03","conditions":["Hypertension","Stroke"],"enrollment":533,"completionDate":"2013-03"},{"nctId":"NCT01631227","phase":"PHASE3","title":"Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension","status":"COMPLETED","sponsor":"Abbott","startDate":"2012-06","conditions":["Essential Hypertension"],"enrollment":665,"completionDate":"2013-04"},{"nctId":"NCT01087749","phase":"PHASE1","title":"Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-03","conditions":["Kidney Disease"],"enrollment":24,"completionDate":"2012-12"},{"nctId":"NCT00160160","phase":"NA","title":"Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2004-10","conditions":["Hypertension","Type 2 Diabetes"],"enrollment":440,"completionDate":""},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":["Hypertension"],"enrollment":52,"completionDate":"2005-09"},{"nctId":"NCT00438945","phase":"PHASE4","title":"The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Regional Hospital Holstebro","startDate":"2007-01","conditions":["Essential Hypertension"],"enrollment":18,"completionDate":"2008-01"},{"nctId":"NCT00409903","phase":"PHASE4","title":"The Effect of Eprosartan on Hormones and Kidney Function in Healthy Humans.","status":"COMPLETED","sponsor":"Regional Hospital Holstebro","startDate":"2006-11","conditions":["Healthy"],"enrollment":18,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"Teveten HCT"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148645","MMSL":"186415","NDDF":"007065","UNII":"2KH13Z0S0Y","VUID":"4021199","CHEBI":"CHEBI:4814","VANDF":"4021199","INN_ID":"7223","RXNORM":"236878","UMLSCUI":"C0287041","chemblId":"CHEMBL1200987","ChEMBL_ID":"CHEMBL813","KEGG_DRUG":"D02082","DRUGBANK_ID":"DB00876","PUBCHEM_CID":"5281037","SNOMEDCT_US":"129488003","IUPHAR_LIGAND_ID":"588","SECONDARY_CAS_RN":"144143-96-4","MESH_SUPPLEMENTAL_RECORD_UI":"C068373"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1997-","companyName":"Abbvie","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.1 hours","clearance":"1.9 mL/min/kg","bioavailability":"13%","fractionUnbound":"0.017%","volumeOfDistribution":"0.17 L/kg"},"publicationCount":383,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"C09CA02","allCodes":["C09CA02","C09DA02"]},"biosimilarFilings":[],"originalDeveloper":"Abbvie","recentPublications":[{"date":"2026 Jan 7","pmid":"41378994","title":"Decoding the Neuroprotective Intervention of Angiotensin Receptor Blockers: A Multimodal Approach Using In Silico Network Pharmacology, Molecular Modeling, and In Vivo Validation of Key Markers.","journal":"ACS chemical neuroscience"},{"date":"2025 Dec","pmid":"40886946","title":"Eprosartan alleviates the traumatic brain injury-induced multi-organ dysfunction syndrome in mice via AT(1)R/SNS/HMGB1 blockade and PDL-1 modulation.","journal":"Molecular and cellular neurosciences"},{"date":"2025 Jun 26","pmid":"40440958","title":"Modulating the renin-angiotensin system by eprosartan or xanthenone drives microglial M2 polarization in a rat model of Parkinson's disease via regulating the interplay between MKP-1/ miR-155 /SOCS1 and PP2A signaling network.","journal":"International immunopharmacology"},{"date":"2025 Apr 4","pmid":"40190631","title":"Unraveling PPARβ/δ nuclear receptor agonists via a drug-repurposing approach: HTVS-based ligand identification, molecular dynamics, pharmacokinetics, and in vitro anti-steatotic validation.","journal":"RSC advances"},{"date":"2025","pmid":"39945248","title":"Eprosartan Reduces Inflammation and Oxidative Stress in Ethanol-induced Hepatotoxicity.","journal":"Current pharmaceutical design"}],"combinationProducts":[{"brandName":"Teveten HCT","ingredients":"eprosartan + hydrochlorothiazide"}],"companionDiagnostics":[],"genericManufacturers":1,"_genericFilersChecked":true,"genericManufacturerList":["Pharmobedient"],"status":"approved","companyName":"Abbvie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"1997","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1997-12-22T00:00:00.000Z","mah":"ABBVIE","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1997-12-22T00:00:00.000Z","mah":"ABBVIE","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1997-12-22T00:00:00.000Z","mah":"ABBVIE","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1997-12-22T00:00:00.000Z","mah":"ABBVIE","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1997-12-22T00:00:00.000Z","mah":"ABBVIE","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1997-12-22T00:00:00.000Z","mah":"ABBVIE","brand_name_local":null,"application_number":""},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:39:38.848630+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}